Mouse models of kras-mutant colorectal cancer: Valuable gemms for drug testing?

Clinical Cancer Research

Volumn 19, Issue 11, 2013, Pages 2794-2796

  Di Nicolantonio, Federica ^a,b   Bardelli, Alberto ^a,b,c  

^a UNIVERSITY OF TURIN   (Italy)

^b CANDIOLO CANCER INSTITUTE   (Italy)

^c FIRC INSTITUTE OF MOLECULAR ONCOLOGY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; APC PROTEIN; CRE RECOMBINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN P53; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER MODEL; CANCER SURVIVAL; CELL PROLIFERATION; COLORECTAL CANCER; DRUG TARGETING; EXPERIMENTAL NEOPLASM; GENE EXPRESSION; GENE FREQUENCY; GENE SILENCING; GENOTYPE; HUMAN; NONHUMAN; ONCOGENE K RAS; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN PHOSPHORYLATION; TRANSGENIC MOUSE; TUMOR MICROENVIRONMENT;

ANIMALS; COLONIC NEOPLASMS; HUMANS; MUTATION; RAS PROTEINS;

EID: 84878989582     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-0339     Document Type: Article

References (11)

1. Martin ES, Belmont PJ, Sinnamon MJ, Georgeon Richard L, Yuan J, Coffee EM, et al. Development of a colon cancer GEMM-derived orthotopic transplant model for drug discovery and validation. Clin Cancer Res 2013;19:2929-40.
2. Fearon ER, Vogelstein B. Agenetic model for colorectal tumorigenesis. Cell 1990;61:759-67.
3. Smith G, Carey FA, Beattie J, Wilkie MJ, Lightfoot TJ, Coxhead J, et al. Mutations in APC, Kirsten-ras, and p53-alternative genetic pathways to colorectal cancer. Proc Natl Acad Sci U S A 2002;99:9433-8. (Pubitemid 34764631)
4. Wood LD, Parsons DW, Jones S, Lin J, Sjoblom T, Leary RJ, et al. The genomic landscapes of human breast and colorectal cancers. Science 2007;318:1108-13. (Pubitemid 350134889)
5. Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012;487:330-7.
6. Shibata H, Toyama K, Shioya H, Ito M, Hirota M, Hasegawa S, et al. Rapid colorectal adenoma formation initiated by conditional targeting of the Apc gene. Science 1997;278:120-3.
7. Hung KE, Maricevich MA, Richard LG, Chen WY, Richardson MP, Kunin A, et al. Development of a mouse model for sporadic and metastatic colon tumors and its use in assessing drug treatment. Proc Natl Acad Sci U S A 2010;107:1565-70.
8. Yeh JJ, Routh ED, Rubinas T, Peacock J, Martin TD, Shen XJ, et al. KRAS/BRAF mutation status and ERK1/2 activation as biomarkers for MEK1/2 inhibitor therapy in colorectal cancer. Mol Cancer Ther 2009;8:834-43.
9. Singh A, Sweeney MF, Yu M, Burger A, Greninger P, Benes C, et al. TAK1 inhibition promotes apoptosis in KRAS-dependent colon cancers. Cell 2012;148:639-50.
10. Migliardi G, Sassi F, Torti D, Galimi F, Zanella ER, Buscarino M, et al. Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas. Clin Cancer Res 2012;18:2515-25.
11. Dienstmann R, Serpico D, Rodon J, Saura C, Macarulla T, Elez E, et al. Molecular profiling of patients with colorectal cancer and matched targeted therapy in phase I clinical trials. Mol Cancer Ther 2012;11:2062-71.